Investigating the cytotoxic effect of aqueous extract of Peganum harmala on oxaliplatin-resistant HCT116 cell line and evaluating BAX gene expression

Salimizadeh, Zahra; Tahmasebi Enferadi, Sattar; Majidizadeh, Tayebeh; Jalal, Razieh; Mahjoubi , Frouzandeh

[Home ] [Archive]

[ فارسی ]

Journal of Ilam University of Medical Sciences

Main Menu

Home

Journal Information

Articles archive

Publication Ethics

Peer Review Process

Indexing Databases

For Authors

For Reviewers

Subscription

Contact us

Site Facilities

Google Scholar Metrics

	All	Since 2020
Citations	6898	3526
h-index	29	19
i10-index	199	78

Search in website

Receive site information

Registered in

Volume 33, Issue 1 (4-2025)

Journal of Ilam University of Medical Sciences 2025, 33(1): 111-126

Back to browse issues page

Investigating the cytotoxic effect of aqueous extract of Peganum harmala on oxaliplatin-resistant HCT116 cell line and evaluating BAX gene expression

Zahra Salimizadeh¹

, Sattar Tahmasebi Enferadi²

, Tayebeh Majidizadeh¹

, Razieh Jalal³

, Frouzandeh Mahjoubi ^*⁴

1- Dept of Medical Genetic, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran
2- Dept of Plant Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran
3- Dept of Chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran
4- Dept of Medical Genetic, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran , frouz@nigeb.ac.ir

Abstract: (173 Views)

Introduction: Colorectal cancer is a prevalent digestive tract malignancy, with oxaliplatin being an effective chemotherapeutic drug, but long-term use can lead to drug resistance. It is crucial to develop methods to reduce CRC cells' oxaliplatin resistance. Peganum harmala L. (P. harmala), is a common anticancer treatment in traditional medicine.
Materials & Methods: The study used P. harmala seeds extract to treat oxaliplatin-resistant HCT116 cells for 24 and 48 hours. Cell viability was determined using the MTT assay, and RNA extraction was performed from the treated and control cells. cDNA synthesis was performed using extracted RNAs, and the expression level of the BAX gene was analyzed using Real-Time PCR. Statistical analysis was conducted using Graph Pad Prism 8 software and t-test, with a significance level of P less than 0.05.
Results: Findings indicated a significant correlation between the increase in the concentration of extract and the percentage of dead cells. The cytotoxicity of the aqueous extract of P. harmala seeds significantly increased from 24 to 48 hours in oxaliplatin-resistant HCT116 cells. Furthermore, a significant and considerable upregulation in the relative expression of the BAX gene was observed compared to the control group (P<0.001).
Conclusion: The cytotoxic effect of the aqueous extract of P. harmala is dose- and time-dependent. The extract has the potential to induce apoptosis in colorectal cancer cells by regulating apoptosis-related genes, particularly by upregulating pro-apoptotic genes such as BAX.

Keywords: oxaliplatin, BAX, colorectal cancer, P. harmala, aqueous extract

Full-Text [PDF 1056 kb] (40 Downloads)

Type of Study: Research | Subject: Molecular Genetics
Received: 2024/09/24 | Accepted: 2025/01/18 | Published: 2025/04/16

References

1. Avella P, Vaschetti R, Cappuccio M, Gambale F, Rafanelli F, Brunese M, et al. The role of liver surgery in simultaneous synchronous colorectal liver metastases and colorectal cancer resections: a literature review of 1730 patients underwent open and minimally invasive surgery. Minerva Surg. 2022;77:582-90. doi: 10.23736/S2724-5691.22.09716-7.

2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49. doi: 10.3322/caac.21660.

3. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23-30. doi: 10.1200/JCO.2004.09.046.

4. Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16:979-89. doi: 10.1016/S1470-2045(15)00159-X.

5. Adebayo AS, Agbaje K, Adesina SK, Olajubutu O. Colorectal cancer: disease process, current treatment options, and future perspectives. Pharmaceutics. 2023;15:2620. doi: 10.3390/pharmaceutics15112620.

6. Yin J, Wang L, Wang Y, Shen H, Wang X, Wu L. Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-β/Smad2/3 signaling pathway. Onco Targets Ther. 2019;12:3893. doi: 10.2147/OTT.S199601.

7. Han W, Yin H, Ma H, Wang Y, Kong D, Fan Z. Curcumin regulates ERCC1 expression and enhances oxaliplatin sensitivity in resistant colorectal cancer cells through its effects on miR-409-3p. Evid Based Complement Alternat Med. 2020;2020. doi: 10.1155/2020/8394574.

8. Wen K, Fu Z, Wu X, Feng J, Chen W, Qian J. Oct-4 is required for an antiapoptotic behavior of chemoresistant colorectal cancer cells enriched for cancer stem cells: effects associated with STAT3/Survivin. Cancer Lett. 2013;333:56-65. doi: 10.1016/j.canlet.2013.01.009.

9. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer: mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 2000;11:265-83. doi: 10.1016/s0928-0987(00)00114-7.

10. Schuell B, Gruenberger T, Kornek G, Dworan N, Depisch D, Lang F, et al. Side effects during chemotherapy predict tumour response in advanced colorectal cancer. Br J Cancer. 2005;93:744-8. doi: 10.1038/sj.bjc.6602783.

11. Fridlender M, Kapulnik Y, Koltai H. Plant derived substances with anti-cancer activity: from folklore to practice. Front Plant Sci. 2015;6:163161. doi: 10.3389/fpls.2015.00799.

12. Choudhari AS, Mandave PC, Deshpande M, Ranjekar P, Prakash O. Phytochemicals in cancer treatment: From preclinical studies to clinical practice. Front Pharmacol. 2020;10:1614. doi: 10.3389/fphar.2019.01614.

13. Browning DD, Kwon IK, Wang R. cGMP-dependent protein kinases as potential targets for colon cancer prevention and treatment. Future Med Chem. 2010;2:65-80. doi: 10.4155/fmc.09.142.

14. Vijayalakshmi M, Meganathan S, Surendhar SK, Umamaheswari A, Lakshmana Prabu S. Exploring the Systematic Anticancer Mechanism in Selected Medicinal Plants: A Review. Oncol Adv. 2024;2:141-7. doi: 10.14218/OnA.2024.00012.

15. Benarba B, Pandiella A. Colorectal cancer and medicinal plants: Principle findings from recent studies. Biomed Pharmacother. 2018;107:408-23. doi : 10.1016/j.biopha.2018.08.006.

16. Mashreghi M, Niknia S. The effect of Peganum harmala and Teucrium polium alcoholic extracts on growth of Escherichia coli O157. Jundishapur J Microbiol. 2012;5:511-5. doi:10.5812/jjm.3665.

17. Ababou A, Chouieb M, Bouthiba A, Saidi D, Bouzina MMH, Mederbal K. Spatial pattern analysis of Peganum harmala on the salted lower Chelif plain, Algeria. Turk J Bot. 2013;37:111-21. doi:10.3906/bot-1202-16.

18. Lamchouri F, Zemzami M, Jossang A, Abdellatif A, Israili ZH, Lyoussi B. Cytotoxicity of alkaloids isolated from Peganum harmala seeds. Pak J Pharm Sci. 2013;26:699-706.

19. Jalali A, Dabaghian F, Zarshenas MM. Alkaloids of Peganum harmala: Anticancer biomarkers with promising outcomes. Curr Pharm Des. 2021;27:185-96. doi:10.2174/1381612826666201125103941.

20. Moloudizargari M, Mikaili P, Aghajanshakeri S, Asghari MH, Shayegh J. Pharmacological and therapeutic effects of Peganum harmala and its main alkaloids. Pharmacogn Rev. 2013;7:199. doi: 10.4103/0973-7847.120524.

21. Moussa TA, Almaghrabi OA. Fatty acid constituents of Peganum harmala plant using Gas Chromatography–Mass Spectroscopy. Saudi J Biol Sci. 2016;23:397-403. doi: 10.1016/j.sjbs.2015.04.013.

22. Niazi S, Tahmasebi Enferadi S, Ghaderitabar H. Variation of Main Alkaloids and Fatty Acids among Five Natural Populations of Peganum harmala L. from Iran. J Med Plants By-Prod. 2021;10:45-52. doi:10.22092/jmpb.2020.128202.1151.

23. Tarkowská D. A fast and reliable UHPLC–MS/MS-based method for screening selected pharmacologically significant natural plant indole alkaloids. Molecules. 2020;25:3274. doi: 10.3390/molecules25143274.

24. Burman MD, Bag S, Ghosal S, Karmakar S, Pramanik G, Chinnadurai RK, et al. Exploring the Structural Importance of the C3═ C4 Double Bond in Plant Alkaloids Harmine and Harmaline on Their Binding Interactions with Hemoglobin. ACS Omega. 2023;8:37054-64. doi: doi: 10.1021/acsomega.3c04432.

25. Uddin MJ, Xu S, Crews BC, Aleem AM, Ghebreselasie K, Banerjee S, et al. Harmaline analogs as substrate-selective cyclooxygenase-2 inhibitors. ACS Med Chem Lett. 2020;11:1881-5. doi: 10.1021/acsmedchemlett.9b00555.

26. Yao P, Yao P, Ku X, Yang J. Harmine suppresses the malignant phenotypes and PI3K activity in breast cancer. Anticancer Drugs. 2023;34:373-83. doi: 10.1097/CAD.0000000000001462.

27. Rashidi M, Mahmoudian E, Mirzaei S, Mazloomi SN, Bazi A, Azadeh H, et al. Harmaline downregulates angiogenesis markers and suppresses the growth of 4T1 breast cancer cells in vivo and in vitro. Chem Biol Interact. 2022;365:110087. doi: 10.1016/j.cbi.2022.110087.

28. Yavari N, Emamian F, Yarani R, Reza Mohammadi-Motlagh H, Mansouri K, Mostafaie A. In vitro inhibition of angiogenesis by heat and low pH stable hydroalcoholic extract of Peganum harmala seeds via inhibition of cell proliferation and suppression of VEGF secretion. Pharm Biol. 2015;53:855-61. doi: 10.3109/13880209.2014.946057.

29. Hamsa T, Kuttan G. Harmine inhibits tumour specific neo-vessel formation by regulating VEGF, MMP, TIMP and pro-inflammatory mediators both in vivo and in vitro. Eur J Pharmacol. 2010;649:64-73. doi: 10.1016/j.ejphar.2010.09.010.

30. Zhang Y, Shi X, Xie X, Laster KV, Pang M, Liu K, et al. Harmaline isolated from Peganum harmala suppresses growth of esophageal squamous cell carcinoma through targeting mTOR. Phytother Res. 2021;35:6377-88. doi: 10.1002/ptr.7289.

31. Ruan S, Jia F, Li J. Potential antitumor effect of harmine in the treatment of thyroid cancer. Evid Based Complement Alternat Med. 2017;2017. doi: 10.1155/2017/9402615.

32. Javeed M, Rasul A, Hussain G, Jabeen F, Rasool B, Shafiq N, et al. Harmine and its derivatives: Biological activities and therapeutic potential in human diseases. Bangladesh J Pharmacol. 2018;13:203-13. doi: 10.3329/bjp.v13i3.34990.

33. Pfeffer CM, Singh AT. Apoptosis: a target for anticancer therapy. Int J Mol Sci. 2018;19:448. doi: 10.3390/ijms19020448.

34. Seyed Hassan Tehrani S, Hashemi Sheikh Shabani S, Tahmasebi Enferadi S, Rabiei Z. Growth inhibitory impact of Peganum harmala L. on two breast cancer cell lines. Iran J Biotechnol. 2014;12:8-14. doi:10.5812/IJB.18562.

35. Shabani SHS, Tehrani SSH, Rabiei Z, Enferadi ST, Vannozzi GP. Peganum harmala L.’s anti-growth effect on a breast cancer cell line. Biotechnol Rep. 2015;8:138-43. doi: 10.1016/j.btre.2015.08.007.

36. Qian S, Wei Z, Yang W, Huang J, Yang Y, Wang J. The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol. 2022;12:985363. doi: 10.3389/fonc.2022.985363.

37. Cory S, Adams JM. Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer cell. 2005;8:5-6. doi: 10.1016/j.ccr.2005.06.012.

38. Liu Z, Ding Y, Ye N, Wild C, Chen H, Zhou J. Direct activation of Bax protein for cancer therapy. Med Res Rev. 2016;36:313-41. doi: 10.1002/med.21379.

39. Huang Hj, Yuan Xz. Recent progress in the direct liquefaction of typical biomass. Prog Energy Combust Sci. 2015;49:59-80. doi:10.1016/j.pecs.2015.01.003.

40. Salimizadeh Z, Enferadi ST, Majidizadeh T, Mahjoubi F. Cytotoxicity of alkaloids isolated from Peganum harmala seeds on HCT116 human colon cancer cells. Mol Biol Rep. 2024;51:732. doi: 10.1007/s11033-024-09655-7.

41. Rezaee M, Hajighasemi F. Sensitivity of hematopoietic malignant cells to Peganum harmala seed extract in vitro. J basic clin pathophysiol. 2019;7:21-6. doi: 10.22070/JBCP.2019.3982.1107.

42. Ma Y, Wink M. The beta‐carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells. Phytother Res. 2010;24:146-9. doi: 10.1002/ptr.2860.

43. Wu LW, Zhang JK, Rao M, Zhang ZY, Zhu HJ, Zhang C. Harmine suppresses the proliferation of pancreatic cancer cells and sensitizes pancreatic cancer to gemcitabine treatment. Onco Targets Ther. 2019:4585-93. doi: 10.2147/OTT.S205097.

44. Hayward RL, Macpherson JS, Cummings J, Monia BP, Smyth JF, Jodrell DI. Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect. Mol Cancer Ther. 2004;3:169-78. doi: 10.1158/1535-7163.169.3.2.

45. Almendro V, Ametller E, García-Recio S, Collazo O, Casas I, Augé JM, et al. The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin. PLoS One. 2009;4:e4728. doi: 10.1371/journal.pone.0004728.

46. Fan Y, Zeng F, Ma L, Zhang H. Effects of β-carboline alkaloids from Peganum harmala on the FAK/PI3K/AKT/Mtor pathway in human gastric cancer cell line SGC-7901 and tumor-bearing mice. Pak J Pharm Sci. 2021;34. doi : 10.36721/PJPS.2021.34.3.REG.891-898.1.

47. Hamsa TP, Kuttan G. Harmine activates intrinsic and extrinsic pathways of apoptosis in B16F-10 melanoma. Chin Med. 2011;6:1-8. doi: 10.1186/1749-8546-6-11.

48. Ding Y, He J, Huang J, Yu T, Shi X, Zhang T, et al. Harmine induces anticancer activity in breast cancer cells via targeting TAZ. Int J Oncol. 2019;54:1995-2004. doi: 10.3892/ijo.2019.4777.

49. Guo B, Cao S, Tóth K, Azrak RG, Rustum YM. Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma. Clin Cancer Res. 2000;6:718-24.

50. Zhao Y, Xiao B, Chen B, Qiao T, Fan D. Upregulation of drug sensitivity of multidrug-resistant SGC7901/VCR human gastric cancer cells by bax gene transduction. Chin Med J (Engl). 2000;113:977-80.

Send email to the article author

Add your comments about this article

Mendeley

Zotero

RefWorks

Salimizadeh Z, Tahmasebi Enferadi S, Majidizadeh T, Jalal R, Mahjoubi F. Investigating the cytotoxic effect of aqueous extract of Peganum harmala on oxaliplatin-resistant HCT116 cell line and evaluating BAX gene expression. J. Ilam Uni. Med. Sci. 2025; 33 (1) :111-126
URL: http://sjimu.medilam.ac.ir/article-1-8413-en.html

Rights and permissions
	This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Volume 33, Issue 1 (4-2025)

Back to browse issues page

Persian site map - English site map - Created in 0.16 seconds with 41 queries by YEKTAWEB 4701